A federal appeals court on Thursday probed a Boston federal judge’s certification of an antitrust class action challenging AstraZeneca PLC’s “pay for delay” settlements with three generic drug makers.
The U.S. Court of Appeals for the First Circuit heard oral argument in In re Nexium Antitrust Litigation over AstraZeneca’s settlements to delay competing generic gastrointestinal drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
